Wednesday, 22 Jan 2020

PsA/SpA

Datesort ascending Type Title Save
12 Sep 2019 Social Study of the Taiwan National Health Insurance database shows that ankylosing spondylitis patients may have a higher risk of diabetes (IRR 1.21) compared to non-AS group (1.43 vs 1.19 per 100 person-years, 95% CI 1.02 to 1.43, p=0.025). https://t.co/71EfDtwK2g
09 Sep 2019 Social RheumNow Podcast is up - Do’s and Don’ts in Spondylitis (9.5.19). View it here>> https://t.co/OU9mAdO4Iw or listen to the Podcast on iTunes or SoundCloud>> https://t.co/TiBevXDyAH
09 Sep 2019 News Anti-IL-23 Beats IL-17 in Plaque Psoriasis
06 Sep 2019 Social A systematic review of mental health issues in #PsA shows that psoriatic arthritis patients have high prevalence of Anxiety - 33% have mild anxiety & 21% moderate. Depression is mild in 20% & 14% have moderate depression. Pain is worse with both. https://t.co/XU1HVDlVal
29 Aug 2019 Social Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year. https://t.co/0DkfUG5alt
27 Aug 2019 News Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)
26 Aug 2019 News ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
26 Aug 2019 Social FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA. Recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. https://t.co/S8zwuYuK2H
23 Aug 2019 Social European Study of 24,195 axSpA pts shows that 1st TNFi resulted in 27% ASDAS inactive disease @6 months & 59% achieved BASDAI <40; 80% continued Rx after 1 year. 1178 patients w/ non-radiographic axSpA had lower 12-mos retention (73%) https://t.co/KJn5eD6wWw
19 Aug 2019 News Skyrizi Outduels Humira in Psoriasis
15 Aug 2019 Social Nurses' Health Study II shows high gluten intake is not assoc w/ a greater risk of Psoriasis (HR 1.15;0.98-1.36), Psoriatic arthritis (HR 1.12;0.78-1.62) or Atopic dermatitis (HR 0.91; 0.66-1.25); 85,185 Pso, 85,324 PsA & 63,443 atopic dermatitis patients. https://t.co/P1eWGZZqKl
01 Aug 2019 News Biologic Therapy Improves Psoriasis and Reduces CV Inflammation
31 Jul 2019 News Joint Surgery Rates Remain High in Psoriatic Arthritis
26 Jul 2019 Social RT @jrheum: The Assessment of Disease Activity in Psoriatic Arthritis: MDA, VLDA, DAPSA, or Something Else? https://t.co/jmyA5KABzM #diseas…
23 Jul 2019 Social Dannish MRI study of 204 people (including 41 #AxSpA) shows that sacroiliac bone marrow edema is nonspecific, seen in 3-39% of non-SpA. Only SI erosions erosions, backfill & ankylosis were specific for axSpA. Few women w/ postpartum pain had SI erosion https://t.co/7iMaKGEafJ
19 Jul 2019 News Fatigue is Driven by Inflammation, Pain, and Chronicity in Psoriatic Arthritis
16 Jul 2019 Social RheumNow Podcast is up! Discussing MAS, CBD, CCP in PsA, Cost savings w/ LLDAS, lupus pregnancy and no go on NGF. View here>> https://t.co/zUclX3ISIs or listen on iTunes or SoundCloud>> https://t.co/DVw7Trrh5r
12 Jul 2019 Social Swedish registry comparison of 541 PsA 40944 non-PsA pregnancies between 1997-2014, shows PsA pregnancies had increased risks for preterm birth (adj OR 1.63) and caesarean deliveries (OR 1.47), but no increased risks for pre-eclampsia, stillbirth https://t.co/L5GcNVbjgQ
11 Jul 2019 Social Analysis of 14 studies &3291 Psoriatic arthritis patients shows the overall frequency of anti-CCP antibodies=9.8%. In PsA, CCP+ was associated with increased risks of polyarthritis (OR 4.4), bone erosion (2.8), and dactylitis (1.98), but not of enthesitis. https://t.co/hM11ZaskfV
04 Jul 2019 Social RT @RheumNow: Analysis from the BSRBR ankylosing spondylitis registry of 2420 AS pts shows that HLA-B27 is associated with an increased ris…